Recommendation of the President – Braftovi (encorafenib)
On 4 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 14/2026 on the reimbursement of the medicinal product Braftovi (encorafenib) under the B.6. drug program. “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)”